Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914).
2/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
1 patients with RS>25 and ET-response and those with RS<25 and e.
I · Intervention 중재 / 시술
ET-alone if N0-1 and RS 0-11 or RS 12-25 and ET-response
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
However, young patients with GnRH+AI had ET-response rates comparable to postmenopausal patients, suggesting that therapy rather than biology accounts for the difference. Combining ET-response and gene expression assessment could help more luminal eBC patients avoid chemotherapy.
OpenAlex 토픽 ·
Cardiac, Anesthesia and Surgical Outcomes
Advanced Breast Cancer Therapies
Growth Hormone and Insulin-like Growth Factors
[BACKGROUND] Low Ki67 after short preoperative endocrine treatment (ET) indicates a favorable prognosis in HR+/HER2- early breast cancer (eBC).
- 표본수 (n) 1,250
APA
O. Gluz, U. Nitz, et al. (2026). Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914).. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2026.04.007
MLA
O. Gluz, et al.. "Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914).." Annals of oncology : official journal of the European Society for Medical Oncology, 2026.
PMID
41999978
Abstract
[BACKGROUND] Low Ki67 after short preoperative endocrine treatment (ET) indicates a favorable prognosis in HR+/HER2- early breast cancer (eBC). We investigated predictors of ET-response in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials.
[PATIENTS AND METHODS] ET-response (Ki67 ≤10%) after 2-4-week standard ET, recurrence score (RS), and nodal status were used for treatment allocation. In ADAPT-HR+/HER2-, clinical high-risk patients received ET-alone if N0-1 and RS 0-11 or RS 12-25 and ET-response. In ADAPTcycle, N0-1 patients with RS>25 and ET-response and those with RS<25 and e.g., ET-non-response, N2-3 patients with RS≤25 and ET-response, were randomized to (neo)adjuvant chemotherapy or aromatase inhibitor (AI)+ribociclib. Predictors of ET-response were identified through multivariable logistic regression models.
[RESULTS] 3,675 patients from ADAPT-HR+/HER2- (≤50 years and premenopausal, ≤50y: N=1,250; >50 years or postmenopausal, >50y: N=2,425) and 4,239 from the ADAPTcycle screening cohort (≤50y: N=1,336; >50y: N=2,903) were analyzed. ET-response rates were higher after AI (ADAPT-HR+/HER2-/ADAPTcycle: 81.4%/76.7%) vs. tamoxifen (ADAPT-HR+/HER2-/ADAPTcycle: 40.1%/34.7%) in both age groups, with further improvement by ovarian function suppression (OFS) in premenopausal patients. Premenopausal patients with GnRH+AI had similar ET-response rates as postmenopausal patients. ET-response predictors included AI use (+OFS in premenopausal), age >50y, lower RS and baseline Ki67 levels, and higher expression of estrogen receptor (by immunohistochemistry) and HER2 (by Oncotype DX™). In ADAPT-HR+/HER2-, 5-year dDFS in ET-responders was markedly higher vs. non-responders even in chemotherapy-treated N0-1 patients with RS>25 (87.0 vs. 80.7%) and it was only slightly lower vs. RS 12-25 group.
[CONCLUSIONS] We observed similar ET-response rates in two large phase III trials. Postmenopausal patients (mostly receiving AI) had higher ET-response rates compared to younger patients. However, young patients with GnRH+AI had ET-response rates comparable to postmenopausal patients, suggesting that therapy rather than biology accounts for the difference. Combining ET-response and gene expression assessment could help more luminal eBC patients avoid chemotherapy.
[PATIENTS AND METHODS] ET-response (Ki67 ≤10%) after 2-4-week standard ET, recurrence score (RS), and nodal status were used for treatment allocation. In ADAPT-HR+/HER2-, clinical high-risk patients received ET-alone if N0-1 and RS 0-11 or RS 12-25 and ET-response. In ADAPTcycle, N0-1 patients with RS>25 and ET-response and those with RS<25 and e.g., ET-non-response, N2-3 patients with RS≤25 and ET-response, were randomized to (neo)adjuvant chemotherapy or aromatase inhibitor (AI)+ribociclib. Predictors of ET-response were identified through multivariable logistic regression models.
[RESULTS] 3,675 patients from ADAPT-HR+/HER2- (≤50 years and premenopausal, ≤50y: N=1,250; >50 years or postmenopausal, >50y: N=2,425) and 4,239 from the ADAPTcycle screening cohort (≤50y: N=1,336; >50y: N=2,903) were analyzed. ET-response rates were higher after AI (ADAPT-HR+/HER2-/ADAPTcycle: 81.4%/76.7%) vs. tamoxifen (ADAPT-HR+/HER2-/ADAPTcycle: 40.1%/34.7%) in both age groups, with further improvement by ovarian function suppression (OFS) in premenopausal patients. Premenopausal patients with GnRH+AI had similar ET-response rates as postmenopausal patients. ET-response predictors included AI use (+OFS in premenopausal), age >50y, lower RS and baseline Ki67 levels, and higher expression of estrogen receptor (by immunohistochemistry) and HER2 (by Oncotype DX™). In ADAPT-HR+/HER2-, 5-year dDFS in ET-responders was markedly higher vs. non-responders even in chemotherapy-treated N0-1 patients with RS>25 (87.0 vs. 80.7%) and it was only slightly lower vs. RS 12-25 group.
[CONCLUSIONS] We observed similar ET-response rates in two large phase III trials. Postmenopausal patients (mostly receiving AI) had higher ET-response rates compared to younger patients. However, young patients with GnRH+AI had ET-response rates comparable to postmenopausal patients, suggesting that therapy rather than biology accounts for the difference. Combining ET-response and gene expression assessment could help more luminal eBC patients avoid chemotherapy.